Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Summary
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Official title: A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
315
Start Date
2025-10-15
Completion Date
2028-08-01
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
BMS-986517
Specified dose on specified days
Locations (19)
Local Institution - 0033
Irvine, California, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Local Institution - 0021
Orange, California, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
START - Dallas Fort Worth
Fort Worth, Texas, United States
START San Antonio
San Antonio, Texas, United States
START Mountain Region
West Valley City, Utah, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Herlev and Gentofte Hospital
Copenhagen, Capital Region, Denmark
Odense Universitetshospital
Odense, Region Syddanmark, Denmark
Copenhagen University Hospital Rigshospitalet
Copenhagen, Denmark
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Local Institution - 0026
Málaga, Andalusia, Spain
Local Institution - 0022
Badalona, Barcelona [Barcelona], Spain
Local Institution - 0024
Barcelona, Barcelona [Barcelona], Spain
Local Institution - 0025
Pamplona, Navarre, Spain
Local Institution - 0027
Madrid, Spain
Local Institution - 0023
Madrid, Spain